Preferred Label : Rilzabrutinib;
NCIt definition : An orally bioavailable reversible covalent inhibitor of Bruton's tyrosine kinase (BTK),
with potential immunomodulatory and anti-inflammatory activities. Upon oral administration,
rilzabrutinib inhibits the activity of BTK. This prevents the activation of the B-cell
antigen receptor (BCR) signaling pathway, and the resulting immune activation and
inflammation. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases,
plays an important role in B-lymphocyte development, activation, signaling, proliferation
and survival. In addition to B-cells, BTK is also expressed in other cells of hematopoietic
origin, including monocytes, macrophages, neutrophils, mast cells, eosinophils and
platelets, and plays an important role in both adaptive and innate immune responses.;
UNII : NWN58M4F5T;
CAS number : 1575591-66-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1575591-66-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : PRN-1008; PRN 1008;
NCI Metathesaurus CUI : CL1412267;
Codes from synonyms : 72560;
Origin ID : C174769;
UMLS CUI : C5420945;
Semantic type(s)
- concept_is_in_subset
- has_target
